Targeted Tumor Therapy With a Fusion Protein of an Antiangiogenic Human Recombinant scFv and Yeast Cytosine Deaminase
| Autor: | Christopher Bachran, Patricia Fasold, Peter M. Deckert, Hendrik Fuchs, Diana Bachran, N. Schellmann, Hossein Panjideh |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Teratocarcinoma
Cancer Research Cell Survival Angiogenesis Recombinant Fusion Proteins Immunology Flucytosine Angiogenesis Inhibitors Pichia Cytosine Deaminase law.invention Pichia pastoris Fungal Proteins Mice Antigens Neoplasm law Cell Line Tumor Animals Immunology and Allergy Molecular Targeted Therapy Pharmacology biology Chemistry Cytosine deaminase Prodrug biology.organism_classification Fusion protein Molecular biology Fibronectins Fibronectin Cell culture Recombinant DNA biology.protein Single-Chain Antibodies |
| Zdroj: | Journal of Immunotherapy. 35:570-578 |
| ISSN: | 1524-9557 |
| Popis: | In adults, endothelial cell division occurs only in wound healing, during menstruation, or in diseases such as wet age-related macular degeneration or development of benign or malignant tissues. Angiogenesis is one of the major requirements to supply the fast developing tumor tissue with oxygen and nutrients, and enables it to spread into other tissues far from its origin. We selected the extradomain B (ED-B), a splice variant of fibronectin, which is exclusively expressed in ovaries, uterus, during wound healing, and in tumor tissues, as a target for the development of an innovative antiangiogenic, prodrug-based targeted tumor therapy approach. We designed a fusion protein termed L19CDy-His, consisting of the antibody single chain fragment L19 for targeting ED-B and yeast cytosine deaminase for the conversion of 5-fluorocytosine into cytotoxic 5-fluorouracil. We purified high amounts of the fusion protein from Pichia pastoris that is stable, enzymatically active, and retains 75% of its activity after incubation with human plasma for up to 72 hours. The binding of L19CDy-His to ED-B was confirmed by an enzyme-linked immunosorbent assay and quantified by surface plasmon resonance spectroscopy determining a KD value of 81±7 nM. L19CDy-His successfully decreased cell survival of the murine ED-B-expressing teratocarcinoma cell line F9 upon addition of the prodrug 5-fluorocytosine. Our data demonstrate the suitability of targeting ED-B by L19CDy-His for effective prodrug-based tumor therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|